The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Heteroresistance to Fluconazole and Voriconazole in Cryptococcus neoformans
Open accessAbstract
Cryptococcus neoformans isolates that exhibited unusual patterns of resistance to fluconazole and voriconazole were isolated from seven isolates from two different geographical regions: one isolate from an Israeli non-AIDS patient and six serial isolates from an Italian AIDS patient who had suffered six recurrent episodes of cryptococcal meningitis. Each isolate produced cultures with heterogeneous compositions in which most of the cells were susceptible, but cells highly resistant to fluconazole (MICs, ≥64 μg/ml) were recovered at a variable frequency (7 × 10 −3 to 4.6 × 10 −2 ). Evidence showed that this type of resistance is innate and is unrelated to drug exposure since the Israeli patient had never been treated with azoles or any other antimycotic agents. Analysis of clonal subpopulations of these two strains showed that they exhibited heterogeneous patterns of resistance. The number of subpopulations which grew on fluconazole or voriconazole agar declined progressively with increasing azole concentration without a sharp cutoff point. For the Italian serial isolates, the number of clonal populations resistant to fluconazole (64 μg/ml) and voriconazole (1 μg/ml) increased steadily, yielding the highest number for the isolate from the last episode. Attempts to purify a sensitive subpopulation failed, but clones highly resistant to fluconazole (100 μg/ml) and moderately resistant to voriconazole (1 μg/ml) always produced a homogeneous population of resistant cells. Upon maintenance on drug-free medium, however, the majority of the homogeneously resistant cells of these subclones lost their resistance and returned to the stable initial heteroresistant phenotype. The pattern of heteroresistance was not affected by the pH or osmolarity of the medium but was influenced by temperature. The resistance appeared to be suppressed at 35°C and was completely abolished at 40°C. Although heterogeneity in azole resistance among subpopulations of single isolates has been reported for Candida species, the transient changes in expression of resistance under different growth conditions reported here have not been observed in fungal pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This phenomenon was first described in 1999, when researchers observed that a subset of Cryptococcus cells were able to grow at azole concentrations well above the inhibitory concentration in vitro21.”
From Treatment strategies for cryptococcal infection: challenges, advances and future outlook (2021) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications
Chambers, H. F. “. (1997) · Clinical Microbiology Reviews · doi:10.1128/cmr.10.4.781 · Cited by 1,128
Expression of methicillin resistance in heterogeneous strains of Staphylococcus aureus
Hartman, B. J., & Tomasz, A. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.1.85 · Cited by 265
Wu, S., de LENCASTRE, H., & Tomasz, A. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.20.6036-6042.1996 · Cited by 241
Sanati, H., Belanger, P. H., Fratti, R. A., & Ghannoum, M. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2492 · Cited by 221
Marr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A., & White, T. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2584 · Cited by 166
Persistence of initial infection in recurrent Cryptococcus neoformans meningitis
Spitzer, E. D., Spitzer, S. G., Freundlich, L. F., & Casadevall, A. (1993) · The Lancet · doi:10.1016/0140-6736(93)90354-j · Cited by 165
Susceptibility testing of Cryptococcus neoformans: a microdilution technique
Ghannoum, M. A., Ibrahim, A. S., Fu, Y., Shafiq, M. C., Edwards, J. E., & Criddle, R. S. (1992) · Journal of Clinical Microbiology · doi:10.1128/jcm.30.11.2881-2886.1992 · Cited by 145
Mechanisms of heteroresistance in methicillin-resistant Staphylococcus aureus
Ryffel, C., Strässle, A., Kayser, F. H., & Berger‐Bächi, B. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.724 · Cited by 140
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–139 of 139
Viviani, M. A., & Tortorano, A. M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00009-8 · Cited by 8
Drug Resistance in Cryptococcus neoformans
Hanson, K. E., Alexander, B. D., & Perfect, J. R. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-595-8_20 · Cited by 7
Cutaneous Cryptococcosis in a Patient Affected by Chronic Lymphocytic Leukaemia: A Case Report
Devirgiliis, V., Panasiti, V., Borroni, R. G., Rossi, M., Curzio, M., Riggio, R., Fioriti, D., Nicosia, R., Pietropaolo, V., Tecca, M., et al. (2008) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200802100227 · Cited by 7
Lee, Y. K., & Fothergill, A. W. (2003) · Mycobiology · doi:10.4489/myco.2003.31.2.095 · Cited by 6
Antifungal drug resistance: Significance and mechanisms
Dharmaiah, S., Sherif, R., & Mukherjee, P. K. (2019) · CRC Press eBooks · doi:10.1201/9780429402012-4 · Cited by 6
Antifungal Drug Resistance: Pumps and Permutations
White, T. C., Harry, J. B., & Oliver, B. G. G. (2004) · Springer eBooks · doi:10.1007/978-3-662-10380-7_17 · Cited by 5
Phenotypic diversity and fungal fitness
Avery, S. V. (2005) · Mycologist · doi:10.1017/s0269-915x(05)00205-3 · Cited by 5
Cellular and genetic changes during and after fluconazole exposure in Cryptococcus neoformans
Albehaijani, S. H. I., Huynh, T. T., & Boyce, K. J. (2025) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107519 · Cited by 4
Drug Resistance in Cryptococcosis
Hanson, K. E., Catania, J., Alexander, B. D., & Perfect, J. R. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_20 · Cited by 4
Exploring Cryptococcus neoformans CYP51 and Its Cognate Reductase as a Drug Target
Ruma, Y. N., Keniya, M. V., & Monk, B. C. (2022) · Journal of Fungi · doi:10.3390/jof8121256 · Cited by 4
Montoya, M. C., Wilhoit, K., Murray, D., Perfect, J. R., & Magwene, P. M. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116103 · Cited by 3
de Sousa, N. S. O., Pinheiro, S. B., Cortez, A. C. A., Cruz, K. S., de Souza, É. S., Melhem, M. D. S. C., Frickmann, H., & de Souza, J. V. B. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115488 · Cited by 3
Know Your Enemy: How to Build and Vanquish a Global Fungal Scourge
Wang, X., Li, W., Sun, S., Kozubowski, L., Lee, S. C., Feretzaki, M., & Heitman, J. (2011) · Mycopathologia · doi:10.1007/s11046-011-9484-9 · Cited by 2
Mukherjee, P. K., & Wang, M. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-5 · Cited by 2
Avery, S. V. (2014) · ASM Press eBooks · doi:10.1128/9781555815509.ch13 · Cited by 2
Central Nervous System Infections
(2014) · ClinMicroNow · doi:10.1002/9781683674849.cmm0006 · Cited by 2
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0134 · Cited by 2
Yu, H., Peng, W., Li, H., Zhang, Y., Fu, X., Gong, X., Wei, H., Zhou, Q., Huang, Y., & Cao, D. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00765-25 · Cited by 1
Heteroresistance to fluconazole among isolates of Cryptococcus neoformans in Northern Thailand
Keerativasee, S., Khamwan, C., Boonchoo, M., Khayhan, K., Kummasook, A., Amornthipayawong, D., PrasitTharavichitkul, & Sriburee, P. (2013) · African Journal of Microbiology Research · doi:10.5897/ajmr2013.5958 · Cited by 1
ADACHI, M., Mayumi, K., Nakabayashi, Y., Kondo, M., Tominaga, T., Matsuda, K., & Shinohara, K. (2008) · Yamaguchi Medical Journal · doi:10.2342/ymj.57.9 · Cited by 1
Gutiérrez-Martínez, M. J., Santibáñez, J., Hernández, M. A. L., Chávez-Mayol, J. M., Rodríguez-Piñeyro, O. M., & Bonifáz, A. (2012) · Cited by 1
Lemetayer, J. D., & Sykes, J. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-29836-4_14 · Cited by 1
Goés, L. D. O. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.6.2019.tde-28062019-093429 · Cited by 1
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0134 · Cited by 1
Central Nervous System Infections
(2014) · ClinMicroNow · doi:10.1002/9781683670438.cmm0006 · Cited by 1
An Overview on Cryptococcal Meningitis
Melhem, M. D. S. C., & Pappalardo, M. C. S. M. (2012) · InTech eBooks · doi:10.5772/29488
Caracterização da atividade antifúngica de extrato aquoso de sementes de Allamanda polyantha
Bresciani, F. R. (2013) · Americanae (AECID Library)
Axcell, A. (2012) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Clinically Promising New Triazoles for Systemic Fungal Infections
Neely, M. N., Sheehan, D. J., & Ghannoum, M. A. (2004) · Springer eBooks · doi:10.1007/978-3-662-10380-7_16
Meletis, G. (2012) · InTech eBooks · doi:10.5772/34032
Lemetayer, J. D., & Sykes, J. E. (2023) · Springer eBooks · doi:10.1007/978-3-662-65907-6_14
Kabata, N., Hashimoto, T., Sofue, N., Matsuyoshi, K., Kawabata, N., & Sugie, Y. (2025) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.51.622
Yuan, D., Li, K., Zheng, X., Li, X., Shui, Y., Ying, Y., & Yan, F. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11985-1
de Oliveira, L., Melhem, M. D. S. C., Buccheri, R., Chagas, O. J., Vidal, J. E., & Díaz-Quijano, F. A. (2022) · Figshare · doi:10.6084/m9.figshare.19151184
A case of Cryptococcus laurentii meningitis in an immunocompromised patient: case report
Bhalavi, S., Shendre, P., Lyngdoh, D. D. I. N. B., Channe, N., & Shrikhande, S. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20260263
Yeboah, R., Catania, S., Tong, P., Navarro-Mendoza, M. I., Arques, C. P., Shukla, M. S., Catania, S., Stone, N. R. H., Bicanic, T. A., Heitman, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.10.731255
Biological characterization of Candida parapsilosis haploids induced by voriconazole
Ji, L., Zheng, T., Hu, T., Li, S., Bing, J., Zheng, Q., Chu, H., & Huang, G. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107922
Moreira, I. D. M. B., Silva, I. B., Bisneto, J. F. D. D. V., SOUSA, N. S. O. D., de Almeida, J. D. R., Filho, R. L. L. R., Lazameth-Diniz, N. D. F., Cruz, K. S., Santos, C. S. D. S., Matsuura, A. B. J., et al. (2026) · Medical Mycology · doi:10.1093/mmy/myag102
Pawar, S., Xue, H. H., Wang, S., Marras, S. A. E., & Xue, C. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.01166-26
Metadata
- Authors
- Mondon, P., Petter, R., Amalfitano, G., Luzzati, R., Concia, E., Polacheck, I., & Kwon-Chung, K. J.
- Affiliations
- National Institutes of Health (US)
- University of Verona (IT)
- Hadassah Medical Center (IL)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1999-08
- Volume
- 43
- Issue
- 8
- Pages
- 1856-1861
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC89380
- OpenAlex
- W2000804360
- Cited by
- 139
- References
- 36
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 3 · 2023: 6 · 2022: 11 · 2021: 5 · 2020: 9 · 2019: 7 · 2018: 3 · 2017: 5 · 2016: 3 · 2015: 2 · 2014: 10 · 2013: 7 · 2012: 12
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Cryptococcus neoformans, azole resistance, fluconazole, voriconazole, heteroresistance, clonal subpopulations, cryptococcal meningitis, AIDS, temperature-dependent resistance, loss of resistance, serial isolates
- MeSH terms
- Acquired Immunodeficiency Syndrome, Adult, Amphotericin B, Antifungal Agents, Cryptococcus neoformans, Drug Resistance, Microbial, Humans, Hydrogen-Ion Concentration, Male, Microbial Sensitivity Tests, Osmolar Concentration, Phenotype, Pyrimidines, Staining and Labeling, Temperature, Triazoles, Fluconazole, Meningitis, Fungal, Itraconazole, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review